Perrigo Sales Up 39% On Big Brand Equivalents, Firm Expects Big Box Boost
This article was originally published in The Tan Sheet
Executive Summary
Perrigo reached record growth in its latest quarter on the launches of Prilosec OTC and Zyrtec equivalents, and the private-labeler's momentum will likely build further as market conditions ripen for store brand success
You may also be interested in...
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba
Perrigo Bets On Mexican Private Label Growth With Laboratorios Diba Buy
Perrigo is betting the Mexican store-brand market will grow the way private label did in the U.S. 20 years ago, with its $25 million acquisition of Laboratorios Diba